A Prospective, Randomised, Double Blind, Placebo Controlled Study To Compare The Safety And Efficacy(Percentage change from baseline in bone mineral density at the total hip at 12 months, compared with placebo) Of Subcutaneous Denosumab 60mg 6 monthly In Acute Spinal Cord Injury In Males And Females.
Phase of Trial: Phase II
Latest Information Update: 16 Jul 2019
Price : $35 *
At a glance
- Drugs Denosumab (Primary)
- Indications Fracture; Osteoporosis
- Focus Therapeutic Use
- 24 Jul 2018 Status changed from recruiting to discontinued.
- 11 Jun 2014 New trial record